Ann E. BeasleyAnn E.Beasley

Regularly called upon to contribute insights to deal committees — both on the in-licensing side as well as part of M&A activity. For example, she participated as a key member in the evaluation of a multinational company’s purchase of a China-based vaccine manufacturer — during which she collaborated with company Legal and Compliance personnel to develop a compliance and legal operational checklist for use in deal evaluations.

Has shared her in-house experience with her clients during several years of consulting in the Governance, Risk and Compliance (GRC) space within the life sciences industry, including the intersection with ESG programs. Ann has performed numerous risk assessments and materiality assessments; advised boards of directors on client activities and Board compliance obligations; and led Independent Review Organization (IRO) engagements for companies operating under Corporate Integrity Agreements (CIAs).

She possesses extensive experience advising and managing across the elements of an effective program, including enterprise and compliance risk assessments, written standards, training and communication, governance and oversight, and monitoring and auditing.

In the course of building and leading programs in many different stages, she has developed and delivered trainings, designed and executed monitoring plans and operational engagements such as HCP engagements, including components of FMV, developed external funding systems, helped design, implement and assess patient support programs and third-party risk management programs.